Glycosylated transferrin receptor 1 tumor antigen
OwnerJisu Li, Jason Shapiro +1inventors
InventorsJisu Li, Jason Shapiro, Jack R. Wands
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods for treating or diagnosing cancer.
Claims23
A composition or method comprising a purified human transferrin receptor 1 (TFR1) protein or a purified cell surface glycosylated peptide fragment thereof, for use as a biomarker for detection of malignancy.
A purified monoclonal antibody that binds to a human transferrin receptor 1 (TFR1) for use in immunotherapy, as a vehicle for delivery of anti-tumor compounds, or as a diagnostic agent, wherein said antibody binds to an aberrant glycosylation site of said TFR1.
A method for delivering a cargo molecule to a subject, the method comprising:
- administering an antibody conjugated to said cargo molecule to the subject,
- wherein the antibody binds to a glycosylated human transferrin receptor-1 antigen, and
- wherein said cargo molecule is selected from the group consisting of a therapeutic agent or a detectable label.
A purified glycosylated TFR1 antigen epitope comprising N-linked glycosylation at amino acid position 50 of SEQ ID NO:1 or amino acid position 55 of SEQ ID NO:1.
A purified glycosylated TFR1 antigen epitope comprising O-linked glycosylation at amino acid position 104 of SEQ ID NO:1.
A method of diagnosing a malignancy, comprising contacting a bodily tissue or fluid of a subject with an antibody that binds to TFR1, wherein said TFR1 comprises glycosylation at an aberrant site compared to a wild type TFR1 protein.
Dependencies are inferred from the claim text.